Skip to search formSkip to main contentSkip to account menu

Crohn Disease

Known as: Crohn's disease NOS, disease crohn, eleocolitis 
A condition in which the gastrointestinal tract is inflamed over a long period of time. Regional enteritis usually affects the small intestine and… 
National Institutes of Health

Related topics

Related topics

48 relations
ABCB1 geneABCB1 wt AlleleAdenocarcinoma of the small intestineAphthous Stomatitis

Broader (5)

ColitisDisease as reason for lower g.i. examinationInflammatory Bowel Diseasesautoimmune inflammatory bowel disease

Narrower (2)

Crohn's disease of the ileumIIeocolitis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Infliximab, azathioprine, or combination therapy for Crohn's disease.
BACKGROUND The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease… 
Highly Cited
2010
Highly Cited
2010
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
We undertook a meta-analysis of six Crohn's disease genome-wide association studies (GWAS) comprising 6,333 affected individuals… 
Highly Cited
2008
Highly Cited
2008
Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients
A decrease in the abundance and biodiversity of intestinal bacteria within the dominant phylum Firmicutes has been observed… 
Highly Cited
2008
Highly Cited
2008
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
Several risk factors for Crohn's disease have been identified in recent genome-wide association studies. To advance gene… 
Highly Cited
2007
Highly Cited
2007
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
BACKGROUND & AIMS This study evaluated the efficacy and safety of adalimumab, a fully human, anti-tumor necrosis factor… 
Highly Cited
2004
Highly Cited
2004
Infliximab maintenance therapy for fistulizing Crohn's disease.
BACKGROUND Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with… 
Highly Cited
2001
Highly Cited
2001
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Crohn's disease and ulcerative colitis, the two main types of chronic inflammatory bowel disease, are multifactorial conditions… 
Highly Cited
1999
Highly Cited
1999
Infliximab for the treatment of fistulas in patients with Crohn's disease.
BACKGROUND Enterocutaneous fistulas are a serious complication of Crohn's disease and are difficult to treat. Infliximab, a… 
Highly Cited
1997
Highly Cited
1997
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
Background Studies in animals and an open-label trial have suggested a role for antibodies to tumor necrosis factor… 
Highly Cited
1976
Highly Cited
1976
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)